The Japan Times - Ozempic-maker Novo Nordisk says CEO to step down

EUR -
AED 4.035497
AFN 70.879608
ALL 90.379658
AMD 396.143424
ANG 1.967368
AOA 1008.736213
ARS 1705.722423
AUD 1.631453
AWG 1.977914
AZN 1.846469
BAM 1.955437
BBD 2.213208
BDT 137.250764
BGN 1.948762
BHD 0.414479
BIF 3302.017015
BMD 1.098841
BND 1.41625
BOB 12.818386
BRL 6.34998
BSD 1.098906
BTN 102.65987
BWP 15.382283
BYN 3.297818
BYR 21537.282362
BZD 2.21021
CAD 1.571821
CDF 2520.741106
CHF 0.924713
CLF 0.027761
CLP 1092.599755
CNY 7.325038
CNH 7.326923
COP 3636.086637
CRC 489.513548
CUC 1.098841
CUP 26.373142
CVE 110.378416
CZK 24.374505
DJF 195.285735
DKK 7.474398
DOP 66.425092
DZD 150.659607
EGP 59.025558
ERN 16.482614
ETB 177.297929
FJD 2.525026
FKP 0.833325
GBP 0.832388
GEL 2.845536
GGP 0.833325
GHS 12.90055
GIP 0.833325
GMD 81.314071
GNF 9735.730589
GTQ 8.398517
GYD 229.816733
HKD 8.621808
HNL 29.756236
HRK 7.507243
HTG 143.974573
HUF 366.533838
IDR 20063.736666
ILS 3.576337
IMP 0.833325
INR 102.714101
IQD 1664.744019
IRR 2119722.948453
ISK 136.806024
JEP 0.833325
JMD 174.62757
JOD 0.779084
JPY 175.300841
KES 142.783348
KGS 96.092572
KHR 4477.776293
KMF 492.280045
KPW 988.957228
KRW 1462.809769
KWD 0.342498
KYD 0.915838
KZT 487.903833
LAK 24765.131862
LBP 98401.206219
LKR 365.675403
LRD 185.429214
LSL 18.614474
LTL 3.244591
LVL 0.664678
LYD 7.09303
MAD 10.954071
MDL 20.121446
MGA 5043.679904
MKD 61.49832
MMK 2307.371362
MNT 3961.860404
MOP 8.881431
MRU 44.673325
MUR 52.590226
MVR 16.886464
MWK 1907.587522
MXN 20.243199
MYR 4.498216
MZN 70.214584
NAD 18.61457
NGN 1484.963102
NIO 40.404225
NOK 10.583871
NPR 164.255991
NZD 2.000209
OMR 0.422499
PAB 1.098876
PEN 3.752544
PGK 4.937917
PHP 69.959931
PKR 303.835236
PLN 4.402341
PYG 6846.72851
QAR 4.005607
RON 5.349172
RSD 117.631014
RUB 90.157894
RWF 1621.889223
SAR 4.127733
SBD 8.941314
SCR 15.183341
SDG 660.951956
SEK 11.133616
SGD 1.41617
SHP 0.831951
SLE 25.05643
SLL 23042.149052
SOS 629.084996
SRD 41.138384
STD 22743.788841
STN 24.888747
SVC 9.615258
SYP 14287.130231
SZL 18.614266
THB 37.170475
TJS 10.126934
TMT 3.845943
TND 3.343226
TOP 2.645746
TRY 55.428803
TTD 7.440686
TWD 36.179446
TZS 2911.931778
UAH 49.816449
UGX 4560.173891
USD 1.098841
UYU 44.643334
UZS 13219.056641
VES 1005.990962
VND 28253.947588
VUV 132.790424
WST 3.079727
XAF 655.957
XAG 0.023206
XAU 0.000285921949
XCD 2.969673
XCG 1.980532
XDR 0.776938
XOF 655.957
XPF 119.331742
YER 259.930263
ZAR 18.599257
ZMK 9890.885316
ZMW 22.51141
ZWL 353.826333
SSP 6534.755674
MXV 2.270971
  • RYCEF

    0.1000

    19.81

    +0.5%

  • VOD

    -0.2500

    16.33

    -1.53%

  • CMSC

    -0.2800

    20.12

    -1.39%

  • RBGPF

    -2.0000

    65

    -3.08%

  • RIO

    -0.2500

    94.16

    -0.27%

  • BTI

    -1.2000

    54.85

    -2.19%

  • NGG

    -0.3000

    74.94

    -0.4%

  • GSK

    -0.3500

    49.35

    -0.71%

  • BCE

    -0.4200

    20.14

    -2.09%

  • CMSD

    -0.3400

    19.93

    -1.71%

  • BP

    -0.9100

    43.52

    -2.09%

  • RELX

    0.1700

    33.24

    +0.51%

  • BCC

    -0.6200

    75.97

    -0.82%

  • AZN

    -1.9400

    164.21

    -1.18%

  • JRI

    0.0000

    10.77

    0%

Ozempic-maker Novo Nordisk says CEO to step down
Ozempic-maker Novo Nordisk says CEO to step down / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File

Ozempic-maker Novo Nordisk says CEO to step down

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake of "market challenges".

Text size:

The company said the decision was made by mutual agreement with the board and that it was searching for a successor for Lars Fruergaard Jorgensen.

Jorgensen will continue "for a period to support a smooth transition to new leadership", Novo Nordisk said in a statement.

The change is being made "in light of the recent market challenges Novo Nordisk has been facing and the development of the company's share price since mid-2024", it said.

At the same time, the company stressed the success it had seen under Jorgensen's stewardship.

"During his eight-year tenure as CEO, Novo Nordisk's sales, profits and share price have almost tripled," Novo Nordisk said.

The 58-year-old Danish executive has spent his entire career at Novo Nordisk, which he joined 34 years ago.

Ozempic, which accounts for 41 percent of Novo Nordisk's sales, is an injectable treatment for diabetes that became wildly popular on social networks for its slimming properties.

Novo Nordisk launched the anti-obesity drug Wegovy, which uses the same molecule but has been directly approved as a weight loss treatment, in the United States in 2021.

Following the success of its treatments, Novo Nordisk rose to become Europe's most valuable company by market capitalisation in September 2023, overtaking French luxury fashion house LVMH, making the company a cornerstone of the Danish economy.

The drugmaker has since been dethroned and reclaimed the spot several times, having last been overtaken for the lead by German tech company SAP in March.

- Facing competition -

Since June 2024, Novo Nordisk's share has fallen by more than half and now ranks as Europe's fourth most valuable company.

The share price dropped more than three percent on the Copenhagen stock exchange following Friday's announcement.

The decline has come as its dominant position has faced several challenges.

Earlier this month, the company cut its full-year sales growth forecast due to competition from copycat versions of its popular GLP-1 injections made in US pharmacies -- a practice known as compounding.

The pharmacies had been allowed to make their own version of Wegovy and Ozempic due to a shortage of the drugs.

But US regulators ruled in February that the shortage had ended and ordered pharmacies to discontinue making the compounded versions.

"We are actively focused on preventing unlawful and unsafe compounding and on efforts to expand patient access to our GLP-1 treatments," Jorgensen said in a statement in early May.

The Danish group had cut its sales forecast from the 16-to-24 percent range to 13-to-21 percent.

Novo Nordisk is also facing competition from US rival Eli Lilly, which makes the anti-obesity injection Zepbound.

Novo Nordisk's shares tumbled last month after Eli Lilly announced a successful clinical trial of diabetes and obesity treatment orforglipron.

Around the world, more than 10 percent of the population suffers from diabetes, for which treatments make up the core of the drugmaker's business.

According to the International Diabetes Federation, the number of diabetic adults is expected to increase by 46 percent by 2045.

The World Obesity Federation also predicts that by 2035, over half of the world's population will be overweight or obese and the global economic impact could then exceed $4 trillion a year.

K.Nakajima--JT